Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEETINGS - "Wie werden Medizinprodukte durch die GKV erstattet?" (Germany) September 2006:

This article was originally published in Clinica

Executive Summary

The method of reimbursement for medtech products in Germany via the statutory sickness funds is the theme of a BVMed/MedInform day-long meeting on September 21 in Berlin entitled "Wie werden Medizinprodukte durch die GKV erstattet?" The seminar will provide an overview of the healthcare and insurance systems, noting that the latter is "highly complex and intransparent". Chairing the session will be Daniela Piossek and Olaf Winkler, both of BVMed. For more details, and to register, go to: http://www.bvmed.de/events/date/medinform210906.html

You may also be interested in...



Pfizer Picks Up EU Pegfilgrastim Approval

Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.

A Stroke Of Luck Boosts Oxford/AZ’s “Vaccine For The World”

AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.

Alvotech Targets Chinese Biosimilars With Yangtze River Deal

Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.

Topics

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel